Page 1

May 17 , 2021 FORTRESS BIOTECH REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights Rolling NDA submission for CUTX - 101 for the treatment of Menkes disease is expected to begin in the second half of 2021 On track to report top - line results from the registration - enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma by year - end 2021 Ended first quarter 2021 with $ 291.5 million in consolidated cash , cash equivalents and restricted cash NEW YORK , May 17 , 2021 ( GLOBE NEWSWIRE ) -- Fortress Biotech , Inc. ( NASDAQ : FBIO ) ( " Fortress " ) , an innovative biopharmaceutical company focused on acquiring , developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost - effectively , today announced financial results and recent corporate highlights for the first quarter ended March 31 , 2021 . Lindsay A. Rosenwald , M.D. , Fortress ' Chairman , President and Chief Executive Officer , said , " Fortress and our partner companies had an exciting start to the year , including the addition and commercial launch of two dermatology products , bringing our total number of marketed products to seven . Moreover , we continued to achieve significant milestones in the advancement of multiple key development programs . Notably , in February , our partner company , Cyprium Therapeutics ( " Cyprium " ) , and Sentynl Therapeutics ( " Sentynl " ) , a wholly owned subsidiary of the Zydus Group , signed a Development and Asset Purchase Agreement for CUTX - 101 for the treatment of Menkes disease . This agreement , which included an $ 8 million upfront payment for the ongoing development of CUTX - 101 , in addition to regulatory and sales milestone payments plus royalties , allows us to potentially maximize the value of this important asset as Cyprium continues to advance CUTX - 101 toward a rolling submission of a New Drug Application ( " NDA ” ) later this year . " Dr. Rosenwald continued , “ Our portfolio continues to grow with more than 25 product candidates across our partner companies , including 17 clinical programs , of which four are pivotal programs . We expect to have a multitude of regulatory and clinical inflection points throughout the remainder of 2021 , including the availability of clinical data from cosibelimab , CAEL - 101 and MB - 106 . Importantly , our diversified business model is supported by a strong balance sheet , as we ended the first quarter with $ 291.5 million in consolidated cash , cash